Welcome to our dedicated page for Stimcell Energetics SEC filings (Ticker: STME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for StimCell Energetics Inc. (STME) provides access to the company’s official disclosures as a healthcare and medical devices issuer focused on cellular energy and microcurrent technology. These filings offer detailed information on its eBalance® microcurrent platform, wellness and anti-aging focus, capital structure and regulatory reporting practices.
Core periodic reports such as Form 10-K annual reports and Form 10-Q quarterly reports present management’s discussion of operations, risk factors, financial statements and updates on the development and commercialization of therapeutic and non-therapeutic products that enhance cellular function. For example, when the company needs additional time to complete a quarterly report, it may file a Form 12b-25 (NT 10-Q), as it has done to explain delays in preparing financial and business information while indicating an expected filing within the allowed extension period.
Current reports on Form 8-K document material events and corporate developments. StimCell Energetics has used Form 8-K to furnish information about its service agreement with the St. Boniface Hospital Albrechtsen Research Centre to study the eBalance® device’s impact on mitochondrial function in cultured sensory neurons, attaching the related news release as an exhibit under Regulation FD. Similar filings can cover topics such as significant agreements, changes in market listing status, or other events relevant to shareholders.
In addition to these forms, investors may review proxy and governance-related filings, as well as any Form 4 insider transaction reports that may be filed to disclose trades by directors and officers, if applicable. On Stock Titan, AI-powered tools can help interpret lengthy filings by summarizing key points from 10-K and 10-Q reports, highlighting important disclosures about StimCell’s eBalance® technology, research collaborations, marketing agreements and capital markets activities. Real-time updates from EDGAR ensure that new StimCell Energetics filings appear promptly, while AI-generated overviews make complex regulatory documents more accessible to readers who want to understand the company’s regulatory and financial narrative.
StimCell Energetics Inc. entered into an Advisory Services Agreement with Stonegate Capital Partners to provide research coverage and institutional investor outreach. In return for a twelve-month initial term of services, the company agreed to issue 250,000 shares of common stock to Stonegate.
On March 19, 2026, StimCell issued these 250,000 shares as unregistered securities under Rule 506(b) of Regulation D to an accredited investor. A related news release explains that Stonegate will provide quarterly research, investor relations consulting, and targeted institutional investor meetings to help expand awareness of StimCell’s eBalance® technology and broader wellness and longevity platform.
Stimcell Energetics Inc. reported another quarter with no revenue and a larger loss as it continues to fund early-stage biotech development through related-party debt and stock issuance. For the quarter ended November 30, 2025, the company recorded a net loss of $309,748, bringing the six‑month loss to $575,350, up sharply from the prior year as operating expenses more than doubled. General and administrative costs surged due largely to $250,000 of investor relations services paid in shares, while research and development reached $108,344 as work resumed on redesigning the eBalance® home microcurrent device with ADM Tronics.
The balance sheet remains highly stretched, with total assets of $52,345, cash of just $46,159, and a working capital deficit of $1,542,294. Total liabilities were $1,594,639, including $708,923 in notes and advances due to related parties and $546,447 in other related‑party payables. Management discloses an accumulated deficit of $11,436,906 and explicitly states there is substantial doubt about the company’s ability to continue as a going concern without new financing.
To keep operating, Stimcell borrowed $214,248 during the six months from major shareholders and family members under unsecured credit lines bearing 10% interest, compounded monthly and payable on demand. Despite this fragile position, the company is pushing ahead with product development and a new research collaboration with the St. Boniface Hospital Albrechtsen Research Centre to study the eBalance® device’s effects on mitochondrial function in sensory neurons.
Stimcell Energetics Inc. filed a notice that it will be late in submitting its Quarterly Report on Form 10-Q for the period ended November 30, 2025. The company states it could not complete the required financial and business information by the deadline without unreasonable effort or expense.
Stimcell Energetics expects to file the Form 10-Q within 5 calendar days of the prescribed due date, indicating the delay is intended to be short. The notification is signed by Chief Executive Officer David Jeffs, confirming it is an authorized company communication.
Stimcell Energetics Inc. insider Amir Vahabzadeh, who is both a director and a 10% owner, reported a transaction in the company’s common shares dated 12/18/2025. The filing shows a transaction coded "S" involving 16,667 common shares at a price of $0.34 per share. Following this activity, Vahabzadeh is reported to beneficially own 4,164,566 common shares, held directly.
StimCell Energetics Inc. reported that it has signed a service agreement with the St. Boniface Hospital Albrechtsen Research Centre. The collaboration will explore how the company’s proprietary eBalance® device affects mitochondrial function in cultured sensory neurons, aiming to further define the physiological action of the microcurrents generated by the device.
The update was shared through an informational news release furnished under a Regulation FD disclosure, meaning it is provided for information purposes and is not treated as a formally filed financial statement.
Stimcell Energetics Inc. (STME) reported a wider quarterly loss and tight liquidity in its Q1 FY2026 (three months ended August 31, 2025). Net loss was $265,602 versus $66,919 a year ago as operating expenses rose to $252,354 (from $59,636), driven by higher general and administrative costs and renewed R&D. The company ended the quarter with $6,437 in cash and a working capital deficit of $1,393,949. Total liabilities were $1,410,336 and stockholders’ deficit was $(1,393,949).
Management disclosed substantial doubt about going concern. Operations used $108,142 of cash; financing provided $100,000 from a related-party credit line at 10% per annum. The company issued 375,000 shares for services valued at $120,000 during the quarter and a subsequent 125,000 shares valued at $33,750. R&D was $57,309, tied to the eBalance redesign with ADM Tronics. Internal controls over disclosure were assessed as not effective due to lack of segregation of duties. Common shares outstanding were 20,641,272 as of October 14, 2025.